127 related articles for article (PubMed ID: 38803134)
1. DOAC-Remove to counteract the interference of anti-Xa oral anticoagulants on the monitoring of heparin.
Melicine S; Habay C; Ghammad W; Carré J; Diehl JL; Smadja DM; Gendron N; Helley D; Mauge L
Int J Lab Hematol; 2024 May; ():. PubMed ID: 38803134
[TBL] [Abstract][Full Text] [Related]
2. [Interference of oral anti-Xa anticoagulants during monitoring of unfractionated heparin treatments: practical and future attitudes].
Melicine S; Maucorps L; Eschwège V; Carré J; Helley D; Gouin-Thibault I; Gendron N; Nédélec-Gac F; Mauge L
Ann Biol Clin (Paris); 2024 Jun; 82(2):129-138. PubMed ID: 38832688
[TBL] [Abstract][Full Text] [Related]
3. The Relationship between the Initial Anti-factor Xa Measurement and the Duration of Direct Oral Anticoagulant Influence in Patients Transitioning to Heparin.
Plum MD; Hedrick JN; Hockman R; Bazydlo L; Palkimas S
Pharmacotherapy; 2020 Sep; 40(9):880-888. PubMed ID: 32677060
[TBL] [Abstract][Full Text] [Related]
4. Can an anti-Xa assay for unfractionated heparin be used to assess the presence of rivaroxaban in critical situations?
Shin H; Koh EH; Lee GW; Song HN; Kim HY; Park S
J Vasc Surg Venous Lymphat Disord; 2020 Sep; 8(5):741-747. PubMed ID: 32113855
[TBL] [Abstract][Full Text] [Related]
5. [Use of heparin calibrated anti-Xa assay for apixaban and rivaroxaban measurement in the context of regional telestroke activity].
Delassasseigne C; Leroux C; Renou P; Girard D; Lafargue A; Morel S; Belotti PT; Weinmann L
Ann Biol Clin (Paris); 2023 Jul; 81(3):269-279. PubMed ID: 37329142
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels.
Dingus SJ; Smith AR; Dager WE; Zochert S; Nothdurft SA; Gulseth MP
Ann Pharmacother; 2022 Dec; 56(12):1289-1298. PubMed ID: 35499336
[TBL] [Abstract][Full Text] [Related]
7. Influence of Direct Oral Anticoagulants on Anti-Factor Xa Measurements Utilized for Monitoring Heparin.
Macedo KA; Tatarian P; Eugenio KR
Ann Pharmacother; 2018 Feb; 52(2):154-159. PubMed ID: 28862013
[TBL] [Abstract][Full Text] [Related]
8. Anti-factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors.
Stuart M; Johnson L; Hanigan S; Pipe SW; Li SH
J Thromb Haemost; 2020 Jul; 18(7):1653-1660. PubMed ID: 32216028
[TBL] [Abstract][Full Text] [Related]
9. Usefullness of Heparin Calibrated Anti-Xa Activity to Assess Anticoagulant Activity of Apixaban and Rivaroxaban in Emergency Patients Scheduled for Acute Interventions.
Riahi N; Rozen L; Demulder A
J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959250
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
11. A Systemwide Approach for Navigating the Dilemma of Oral Factor Xa Inhibitor Interference With Unfractionated Heparin Anti-Factor Xa Concentrations.
Levito MN; Coons JC; Verrico MM; Szymkowiak A; Legler B; Dueweke EJ; Kane-Gill SL
Ann Pharmacother; 2021 May; 55(5):618-623. PubMed ID: 32885997
[TBL] [Abstract][Full Text] [Related]
12. Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients.
Martin AC; Lessire S; Leblanc I; Dincq AS; Philip I; Gouin-Thibault I; Godier A
Clin Cardiol; 2018 May; 41(5):646-651. PubMed ID: 29532536
[TBL] [Abstract][Full Text] [Related]
13. Study of Modifications Induced by Continued Direct Oral Anticoagulant Therapy during Atrial Fibrillation Ablation Procedures on Standard Hemostasis Parameters.
Muller M; Godet J; Delabranche X; Sattler L; Millard D; Marzak H; Mertes PM; Steib A; Grunebaum L; Jesel L; Tacquard CA
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983237
[TBL] [Abstract][Full Text] [Related]
14. Potential usefulness of activated charcoal (DOAC remove®) for dRVVT testing in patients receiving Direct Oral AntiCoagulants.
Jourdi G; Delrue M; Stepanian A; Valaize J; Foulon-Pinto G; Demagny J; Duchemin J; Nedelec-Gac F; Darnige L; Curis E; Delavenne X; Gaussem P; Siguret V; Gouin-Thibault I
Thromb Res; 2019 Dec; 184():86-91. PubMed ID: 31710863
[TBL] [Abstract][Full Text] [Related]
15. Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure.
Dieplinger B; Egger M; Luft C; Hinterreiter F; Pernerstorfer T; Haltmayer M; Mueller T
J Vasc Surg; 2018 Aug; 68(2):400-407. PubMed ID: 29571622
[TBL] [Abstract][Full Text] [Related]
16. Practical Nomogram Predicting Apixaban or Rivaroxaban Concentrations from Low-Molecular-Weight Heparin Anti-Xa Values: Special Interest in Acute Ischemic Stroke Patients.
Brakta C; Stépanian A; Reiner P; Delrue M; Mazighi M; Curis E; Siguret V
J Stroke; 2023 Jan; 25(1):126-131. PubMed ID: 36592965
[TBL] [Abstract][Full Text] [Related]
17. Perils of Antithrombotic Transitions: Effect of Oral Factor Xa Inhibitors on the Heparin Antifactor Xa Assay.
Ahuja T; Yang I; Huynh Q; Papadopoulos J; Green D
Ther Drug Monit; 2020 Oct; 42(5):737-743. PubMed ID: 32433187
[TBL] [Abstract][Full Text] [Related]
18. Running after Activated Clotting Time Values in Patients Receiving Direct Oral Anticoagulants: A Potentially Dangerous Race. Results from a Prospective Study in Atrial Fibrillation Catheter Ablation Procedures.
Benali K; Verain J; Hammache N; Guenancia C; Hooks D; Magnin-Poull I; Toussaint-Hacquard M; de Chillou C; Sellal JM
J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575348
[TBL] [Abstract][Full Text] [Related]
19. Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Rupp A; Blumenstock G; Zuern CS; Ziemann U; Poli S
J Am Heart Assoc; 2018 Oct; 7(19):e009807. PubMed ID: 30371316
[TBL] [Abstract][Full Text] [Related]
20. Performance Characteristics of DOAC-Remove for Neutralization of the Effects of Apixaban and Rivaroxaban in Lupus Anticoagulant Assays.
Skaugen JM; Sayre C; Hassett AC; Chibisov I; Bontempo F; Meyer MP; Seheult JN
Am J Clin Pathol; 2022 Mar; 157(3):457-469. PubMed ID: 34698336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
